Core Viewpoint - The company's positive profit forecast for 2025 aligns with expectations, maintaining a "Buy" rating with a target price of HKD 75 [1] Group 1: Financial Performance - The company anticipates a revenue growth of over 45% year-on-year for 2025, with gross profit expected to grow over 70% year-on-year and net profit attributable to shareholders projected to increase by over 38% year-on-year [1] - Adjusted net profit, excluding interest income and expenses, is expected to grow over 45% year-on-year, and over 65% year-on-year when excluding foreign exchange impacts [1] - The overall revenue and net profit attributable to shareholders are in line with previous expectations and the company's annual guidance [1] Group 2: Project Development - The company signed 70 new iCMC projects in 2025, accelerating from 53 in 2024, primarily driven by strong growth in the US and China [2] - More than half of the new iCMC projects are attributed to new ADC types, with approximately 20% from dual-antibody ADCs, 17% from XDC, and 10% from non-tumor areas [2] Group 3: Long-term Guidance - The company has disclosed a medium to long-term revenue guidance, expecting a CAGR of 30-35% from 2025 to 2030, surpassing the industry average of 25.6% CAGR [3] - By 2030, it is projected that 20% of revenue will come from XDC types and another 20% from commercialized projects [3] - The company anticipates achieving significant commercial production milestones starting in 2027, with limited revenue contribution expected in 2026 [3] Group 4: Capacity Expansion - The company plans to increase capital expenditure to RMB 1.7 billion in 2026, up from RMB 1.22 billion in 2025, with a long-term capital expenditure guidance exceeding RMB 7 billion by 2029 [4] - The company has established dual production bases in China and Singapore, with the Wuxi DP3 capacity achieving GMP release in July 2025, totaling 7 million bottles per year [4] - Future production lines in Wuxi are expected to double the DP capacity before 2029 [4] Group 5: Strategic Acquisitions - The company is actively pursuing acquisitions to enhance capacity, including a recent acquisition in Hefei to add over 40 kg of peptide conjugate capacity and another acquisition of Dongyao Pharmaceutical for HKD 3.1 billion to add 8 million bottles per year of DP capacity [5] - The company’s global ADC outsourcing market share has reached over 24% [5] Group 6: Valuation - The company maintains a "Buy" rating with a target price of HKD 75, based on updated revenue forecasts for 2025E/2026E/2027E of RMB 5.87 billion, RMB 7.94 billion, and RMB 10.59 billion respectively [6] - Adjusted net profit forecasts are slightly revised to RMB 1.6 billion, RMB 2.12 billion, and RMB 2.91 billion for the same years [6] - The target valuation is set at 38x 2026E PE, reflecting a premium over the historical forward P/E ratio [6]
药明合联(2268.HK)：2025年初步业绩大致符合预期